BACKGROUND: HIV infection has been associated with development of prediabetes and diabetes. Optimum screening practices for these disorders in HIV-infected populations remain unclear. METHODS: We screened 377 adults, with or at-risk for HIV infection, for incident hyperglycaemia (prediabetes or diabetes) using two oral glucose tolerance tests (OGTTs) a median of 18.6 months apart. We determined proportion of incident cases detected by fasting and 120-min plasma glucose levels. Independent predictors of incident hyperglycaemia were identified using logistic regression. RESULTS: The baseline OGTT was consistent with diabetes in 7% of participants and with prediabetes in 31%. Among 352 normoglycaemic and prediabetic participants at baseline, 19 (5%) developed diabetes on follow-up. Among participants normoglycaemic at baseline, an additional 38 (16%) developed prediabetes. Overall 52% of incident hyperglycaemia cases were detected by fasting plasma glucose alone, 33% by a 120-min glucose level alone and 15% by both. Factors independently associated with incident hyperglycaemia included age ≥50 years and body mass index ≥30 kg/m(2). Neither HIV infection nor highly active antiretroviral therapy (HAART) use were associated with increased risk of diabetes. CONCLUSIONS: Incident hyperglycaemia is common among older adults with or at-risk for HIV infection. HIV-infected individuals with classic diabetes risk factors should be screened for hyperglycaemia regardless of HAART use. OGTTs might be the preferred screening strategy in HIV-infected individuals at high risk for developing hyperglycaemia.
BACKGROUND:HIV infection has been associated with development of prediabetes and diabetes. Optimum screening practices for these disorders in HIV-infected populations remain unclear. METHODS: We screened 377 adults, with or at-risk for HIV infection, for incident hyperglycaemia (prediabetes or diabetes) using two oral glucose tolerance tests (OGTTs) a median of 18.6 months apart. We determined proportion of incident cases detected by fasting and 120-min plasma glucose levels. Independent predictors of incident hyperglycaemia were identified using logistic regression. RESULTS: The baseline OGTT was consistent with diabetes in 7% of participants and with prediabetes in 31%. Among 352 normoglycaemic and prediabetic participants at baseline, 19 (5%) developed diabetes on follow-up. Among participants normoglycaemic at baseline, an additional 38 (16%) developed prediabetes. Overall 52% of incident hyperglycaemia cases were detected by fasting plasma glucose alone, 33% by a 120-min glucose level alone and 15% by both. Factors independently associated with incident hyperglycaemia included age ≥50 years and body mass index ≥30 kg/m(2). Neither HIV infection nor highly active antiretroviral therapy (HAART) use were associated with increased risk of diabetes. CONCLUSIONS: Incident hyperglycaemia is common among older adults with or at-risk for HIV infection. HIV-infected individuals with classic diabetes risk factors should be screened for hyperglycaemia regardless of HAART use. OGTTs might be the preferred screening strategy in HIV-infected individuals at high risk for developing hyperglycaemia.
Authors: Andrea A Howard; Michelle Floris-Moore; Julia H Arnsten; Nanette Santoro; Norman Fleischer; Yungtai Lo; Ellie E Schoenbaum Journal: Clin Infect Dis Date: 2005-04-11 Impact factor: 9.079
Authors: Cecilia Yoon; Roy M Gulick; Donald R Hoover; Carlos M Vaamonde; Marshall J Glesby Journal: J Acquir Immune Defic Syndr Date: 2004-12-01 Impact factor: 3.731
Authors: Steven Haffner; Marinella Temprosa; Jill Crandall; Sarah Fowler; Ronald Goldberg; Edward Horton; Santica Marcovina; Kieren Mather; Trevor Orchard; Robert Ratner; Elizabeth Barrett-Connor Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: Arch Intern Med Date: 2005-05-23
Authors: Samantha A Miller; Nanette Santoro; Yungtai Lo; Andrea A Howard; Julia H Arnsten; Michelle Floris-Moore; Galina Moskaleva; Ellie E Schoenbaum Journal: Menopause Date: 2005 May-Jun Impact factor: 2.953
Authors: Mustafa A Noor; Rex A Parker; Edward O'Mara; Dennis M Grasela; Alexander Currie; Sally L Hodder; Fred T Fiedorek; David W Haas Journal: AIDS Date: 2004-11-05 Impact factor: 4.177
Authors: Lindsey Powers Happ; Anne K Monroe; Heather A Young; Yan Ma; Alan E Greenberg; Michael A Horberg; Amanda D Castel Journal: J Acquir Immune Defic Syndr Date: 2020-09-01 Impact factor: 3.731
Authors: Tyler Tate; Amanda L Willig; James H Willig; James L Raper; Linda Moneyham; Mirjam-Colette Kempf; Michael S Saag; Michael J Mugavero Journal: Antivir Ther Date: 2012-09-05
Authors: Line D Rasmussen; Elisabeth R Mathiesen; Gitte Kronborg; Court Pedersen; Jan Gerstoft; Niels Obel Journal: PLoS One Date: 2012-09-12 Impact factor: 3.240